Lutalo Pamela M K, Jordan Natasha, D'Cruz David P
Louise Coote Lupus Unit, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, United Kingdom; King's College School of Medicine, Peter Gorer Department of Immunobiology, 2nd Floor, Borough Wing, Guy's Hospital, Great Maze Pond, London SE1 9RT, United Kingdom.
Louise Coote Lupus Unit, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, United Kingdom; Centre for Molecular and Cellular Biology of Inflammation King's College London - Guy's Campus New Hunt's House, 1st Floor, London SE1 1UL, United Kingdom.
Presse Med. 2014 Jun;43(6 Pt 2):e157-65. doi: 10.1016/j.lpm.2014.03.001. Epub 2014 May 29.
There have been a number of major advances in the treatment of systemic lupus erythematosus and we are now in the era of biologic therapies for this multisystem autoimmune disorder. There has been a greater awareness of the toxicities of the traditional therapies including the recognition that the doses of corticosteroids used in the past have been excessive, resulting in unacceptable toxicities. Other advances have included the development of lower cumulative doses of cyclophosphamide and the widespread acceptance of mycophenolate mofetil for the treatment of lupus nephritis. This review addresses the current management of severe lupus with corticosteroids and cytotoxic agents.
系统性红斑狼疮的治疗已经取得了许多重大进展,我们现在正处于针对这种多系统自身免疫性疾病的生物疗法时代。人们越来越意识到传统疗法的毒性,包括认识到过去使用的皮质类固醇剂量过高,导致了不可接受的毒性。其他进展包括环磷酰胺累积剂量的降低以及霉酚酸酯在狼疮性肾炎治疗中的广泛应用。本综述探讨了使用皮质类固醇和细胞毒性药物对重症狼疮的当前管理。